Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments - PubMed (original) (raw)
. 1999 Mar 23;38(12):3549-58.
doi: 10.1021/bi981874p.
Affiliations
- PMID: 10090741
- DOI: 10.1021/bi981874p
Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments
A Schneider et al. Biochemistry. 1999.
Abstract
One of the hallmarks of Alzheimer's disease is the abnormal state of the microtubule-associated protein tau in neurons. It is both highly phosphorylated and aggregated into paired helical filaments, and it is commonly assumed that the hyperphosphorylation of tau causes its detachment from microtubules and promotes its assembly into PHFs. We have studied the relationship between the phosphorylation of tau by several kinases (MARK, PKA, MAPK, GSK3) and its assembly into PHFs. The proline-directed kinases MAPK and GSK3 are known to phosphorylate most Ser-Pro or Thr-Pro motifs in the regions flanking the repeat domain of tau: they induce the reaction with several antibodies diagnostic of Alzheimer PHFs, but this type of phosphorylation has only a weak effect on tau-microtubule interactions and on PHF assembly. By contrast, MARK and PKA phosphorylate several sites within the repeats (notably the KXGS motifs including Ser262, Ser324, and Ser356, plus Ser320); in addition PKA phosphorylates some sites in the flanking domains, notably Ser214. This type of phosphorylation strongly reduces tau's affinity for microtubules, and at the same time inhibits tau's assembly into PHFs. Thus, contrary to expectations, the phosphorylation that detaches tau from microtubules does not prime it for PHF assembly, but rather inhibits it. Likewise, although the phosphorylation sites on Ser-Pro or Thr-Pro motifs are the most prominent ones on Alzheimer PHFs (by antibody labeling), they are only weakly inhibitory to PHF assembly. This implies that the hyperphosphorylation of tau in Alzheimer's disease is not directly responsible for the pathological aggregation into PHFs; on the contrary, phosphorylation protects tau against aggregation.
Similar articles
- Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites.
Hoffmann R, Lee VM, Leight S, Varga I, Otvos L Jr. Hoffmann R, et al. Biochemistry. 1997 Jul 1;36(26):8114-24. doi: 10.1021/bi970380+. Biochemistry. 1997. PMID: 9201960 - Structural insights into Alzheimer filament assembly pathways based on site-directed mutagenesis and S-glutathionylation of three-repeat neuronal Tau protein.
Dinoto L, Deture MA, Purich DL. Dinoto L, et al. Microsc Res Tech. 2005 Jul;67(3-4):156-63. doi: 10.1002/jemt.20195. Microsc Res Tech. 2005. PMID: 16104002 Review. - Conformational changes specific for pseudophosphorylation at serine 262 selectively impair binding of tau to microtubules.
Fischer D, Mukrasch MD, Biernat J, Bibow S, Blackledge M, Griesinger C, Mandelkow E, Zweckstetter M. Fischer D, et al. Biochemistry. 2009 Oct 27;48(42):10047-55. doi: 10.1021/bi901090m. Biochemistry. 2009. PMID: 19769346 - Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans.
Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Goedert M, et al. Nature. 1996 Oct 10;383(6600):550-3. doi: 10.1038/383550a0. Nature. 1996. PMID: 8849730 - Molecular dissection of the neurofibrillary lesions of Alzheimer's disease.
Goedert M. Goedert M. Arzneimittelforschung. 1995 Mar;45(3A):403-9. Arzneimittelforschung. 1995. PMID: 7763334 Review.
Cited by
- "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.
Xia Y, Prokop S, Giasson BI. Xia Y, et al. Mol Neurodegener. 2021 Jun 5;16(1):37. doi: 10.1186/s13024-021-00460-5. Mol Neurodegener. 2021. PMID: 34090488 Free PMC article. Review. - Tau as a therapeutic target in neurodegenerative disease.
Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI. Himmelstein DS, et al. Pharmacol Ther. 2012 Oct;136(1):8-22. doi: 10.1016/j.pharmthera.2012.07.001. Epub 2012 Jul 10. Pharmacol Ther. 2012. PMID: 22790092 Free PMC article. Review. - An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease.
Cavallini A, Brewerton S, Bell A, Sargent S, Glover S, Hardy C, Moore R, Calley J, Ramachandran D, Poidinger M, Karran E, Davies P, Hutton M, Szekeres P, Bose S. Cavallini A, et al. J Biol Chem. 2013 Aug 9;288(32):23331-47. doi: 10.1074/jbc.M113.463984. Epub 2013 Jun 24. J Biol Chem. 2013. PMID: 23798682 Free PMC article. - Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases.
Wu Y, Ma B, Liu C, Li D, Sui G. Wu Y, et al. Int J Mol Sci. 2024 Sep 23;25(18):10187. doi: 10.3390/ijms251810187. Int J Mol Sci. 2024. PMID: 39337671 Free PMC article. Review. - Accumulation of vesicle-associated human tau in distal dendrites drives degeneration and tau secretion in an in situ cellular tauopathy model.
Lee S, Kim W, Li Z, Hall GF. Lee S, et al. Int J Alzheimers Dis. 2012;2012:172837. doi: 10.1155/2012/172837. Epub 2012 Jan 17. Int J Alzheimers Dis. 2012. PMID: 22315694 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases